Entering text into the input field will update the search result below

OncoMed Pharmaceuticals' (OMED) Management on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

OncoMed Pharmaceuticals (NASDAQ:OMED-OLD) Q4 2017 Earnings Conference Call March 8, 2018 4:30 PM ET


Peter Rahmer - IR

John Lewicki - President

Bob Stagg - SVP of Clinical Research and Development


Maury Raycroft - Jefferies

Soumit Roy - SunTrust Robinson


Good afternoon everyone, and welcome to the OncoMed Pharmaceuticals' Fourth Quarter and Full-Year 2017 Financial Results Conference Call. This call is being recorded.

At this time, for opening remarks and introductions, I'd like to turn the call over to Peter Rahmer, Managing Director at Solebury Trout.

Peter Rahmer

Thank you, Jonathan. Hello everyone, and welcome to OncoMed Pharmaceuticals' financial results and corporate update call for the fourth quarter and full-year of 2017. Leading the call today is John Lewicki, our President. He is joined by Bob Stagg, our Senior Vice President of Clinical Research and Development, and Perry Karsen, Executive Chairman of the Board.

Before we get started, I'd like to remind you that during the conference call, OncoMed will make certain statements that are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our business plans and objectives, and timing and success of clinical trials. Such forward-looking statements are not guarantees of future performance, and therefore you should not put undue reliance upon them.

These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. I refer you to our SEC filings for a discussion of risk factors that could cause our actual results to differ materially from those discussed today. We undertake no obligation to publicly update any forward-looking statements.

With that, I'd now like to turn the call over to OncoMed's President, John Lewicki.

John Lewicki

Thank you, Pete. Good afternoon, everyone and thank you all for joining us for

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

More on OMED-OLD

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.